65 results about "Injuries diseases" patented technology

The invention relates to the field of cytobiology and neurobiology, in particular to an induction medium for inducing neural stem/progenitor cells to be differentiated into oligodendrocyte precursor cells and an induction method and application thereof. The invention adopts the technical scheme that after subjected to preprocessing culture for a certain time by a preprocessing medium, the human neural stem/progenitor cells are rapidly differentiated into the oligodendrocyte precursor cells for expressing oligodendrocyte precursor cell markers such as O4, A2B5, NG2, SOX10, PDGFR (Platelet Derived Growth Factor Receptor) and the like at a high purity under the action of the induction medium; and the key ingredients of the induction medium are bFGF (Basic Fibroblast Growth Factor), PDGF-AA and NT-3 (neurotrophins-3). The method disclosed by the invention and the obtained oligodendrocyte precursor cells can be applied to preparation of a medicament for treating the nervous system injury disease and have wide prospect on the aspects of experiment research and clinical treatment.

The invention belongs to the field of biological medicine, and particularly relates to a Nogo-A receptor binding peptide as well as a derivative and an application thereof. The amino acid residue sequence of the Nogo-A receptor binding peptide is HIYTALV or GFATITG. The derivative of the binding peptide is a product obtained through conventional modification of an amino terminal or a carboxyl terminal of a Nogo-A receptor binding peptide fragment on a Nogo-A receptor binding peptide amino acid side chain group or a product obtained by connecting a label used for peptide or protein detection or purification on the Nogo-A receptor binding peptide. The binding peptide and the derivative of the binding peptide can be bound with NgR in vitro, nerve regeneration is promoted by preventing binding of NgR and Nogo-A, nerve regeneration barriers caused by central nervous injury diseases can be treated, recovery of a central nervous function is promoted, and the binding peptide and the derivative can be widely applied in the medical and biological fields.

The invention relates to medical applications of wedelolactone and derivatives thereof, in particular to the applications in preparing medicines for treating T-cell mediated immunologic injury diseases (chronic hepatitis or autoimmune hepatitis). Traditional Chinese Medicine eclipta has a function of liver protection; wedelolactone is prepared after the active ingredient of eclipta is traced and separated, so the pharmaceutical function is proved to be produced by wedelolactone; the structure of wedelolactone is determined through the spectrum properties and physicochemical properties. Wedelolactone is provided with biological activities: high selective inhibition to ConA stimulated T lymphocyte proliferation, no inhibition to normal peripheral blood lymphocyte (NPBL), and no cytotoxicity; wedelolactone is the active ingredient of Traditional Chinese Medicine with liver protection function; the method for preparing a novel medicine from the active ingredient of eclipta, wedelolactone, has the advantages of discarding the dross and selecting the essential, clear medicinal ingredients, definite function, safety and effectiveness, controllable quality, reducing the adverse drug reaction, and can be suitable for mass production.

The invention relates to the technical field of biology and particularly relates to a composition, application thereof and a health product. The composition has a remarkable effect on relieving acute gastric mucosa injury. The symptom of gastric discomfort caused by gastric mucosa injury can be effectively relieved in the process of taking a solid drink. The solid drink is proven to have advantages on the aspects of protecting and repairing gastric mucosa and be beneficial to promotion of ulcer healing and relief of symptoms of patients. The solid drink provided by the invention is proven to be capable of effectively preventing and/or treating gastric mucosa injury diseases and especially capable of effectively preventing and/or treating acute gastric mucosa injury.

The invention relates to a traditional Chinese medicine for treating cerebrovascular disease sequelae and other nervous system injuries and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw materials: radix hedysari, suncured ginseng, largehead atractylodes rhizomes, tuckahoes, rhizoma polygonati, coix seeds, prepared fleece-flower roots, herba epimedii, deerhorn glue, tortoise shells, herba cistanche, common macrocarpium fruits, barbary wolfberry fruits, Chinese angelica, white paeony roots, red-rooted salvia roots, szechuan lovage rhizomes, suberect spatholobus stems, uniflower swisscentaury roots, scorpioes, centipedes and liquoric roots. The traditional Chinese medicine composition mainly aims to tonify the spleen, supply earth, tonify the kidney and benefit the marrows; and by observing 286 clinical cases of cerebrovascular disease sequelae and 25 cases of other nervous system injury diseases and based on the specified curative effect standard of the traditional Chinese medicine new medicine clinical research guidelines of the State Chinese Medicine Administration Bureau, the effective rate of the cerebrovascular disease sequelae reaches 97 percent, and the effective rate of other nervous system injuries reaches 75 percent.

The invention discloses an adjustable sitting position treatment table, which comprises a length-adjustable base, wherein a treatment seat plate and a treatment table body are arranged at two ends of the base; the end, corresponding to the treatment seat plate, of the treatment table body is provided with a chest supporting pad; the bottom of the chest supporting pad is hinged with the treatment table body; a head-neck supporting pad is arranged at the upper side of the chest supporting pad; the bottom of the head-neck supporting pad is hinged with the top end of the chest supporting pad; the angles of the chest supporting pad and the head-neck supporting pad are adjusted by virtue of hydraulic rods which are hinged on the treatment table body; a concave opening is formed in the middle of the head-neck supporting pad; forearm armrest supporting pads are symmetrically arranged in the middle of the treatment table body; the end, corresponding to the chest supporting pad, of each forearm armrest supporting pad is hinged with the treatment table body; and the angles of the other ends of the forearm armrest supporting pads are adjusted by virtue of hydraulic rods which are hinged on the treatment table body. With the application of the adjustable sitting position treatment table, doctors can treat various injury diseases in cervical vertebra, thoracic vertebra, lumbar vertebra and shoulders, and different adjusting modes can be selected as required; and the treatment table is broad in indications and is good in body position comfort when used for treating patients.

The invention relates to a clinical use of lipoic acid in treatment on pressure-loaded myocardial injury. Lipoic acid is applied to a patient suffering from pressure-loaded myocardial injury based onthe standard treatment so that the activity of the myocardial mitochondrial aldehyde dehydrogenase 2 (ALDH2) is improved, the myocardial mitochondrial energy metabolism is improved, the oxidative stress is inhibited, the cardioprotective effect is produced and the occurrence and development of myocardial injury is delayed. Lipoic acid can improve myocardial mitochondrial energy metabolism throughrecovering the activity of ALDH2 in the myocardial mitochondria, inhibit oxidative stress, prevent the myocardial injury after pressure overload and improve the quality of life of patients. The use provides a novel use for lipoic acid so that the lipoic acid can be well used. The use provides a novel drug research direction for pressure-loaded myocardial injury diseases and has a good applicationprospect.

The invention relates to a technology of biomedicine, concretely to a treatment of a spinal cord injury by transplanting stem cells modified by a neurotrophic factor gene. The treatment comprises: (1) constructing transgenic stem cells, (2) making a spinal cord injury model, (3) performing an inclined plate test, (4) performing an open field test, (5) marking engineering cells, (6) transplanting cells, (7) obtaining organization samples, (8) observing an area of the spinal cord injury, (9) observing survival of the stem cells in vivo, and (10) migrating stem cells in vivo. The transgenic stem cells transplanted to adult rats with the spinal cord injury not only survive and migrate, but also can reduce the area of the spinal cord injury, and promote recovery of neurological function of the rats with the spinal cord injury. Therefore, the transgenic stem cells provide a novel treatment approach for motor neuron injury diseases such as the spinal cord injury.

The invention discloses an application of D609 in preparation of a medicine for preventing and treating retinal injury diseases. The Chinese name of D609 is tricyclic decane-9-yl-dithiocarbonate potassium salt, and the D609 is an antiviral and antitumor small molecular compound, which belongs to a selective inhibitor of phosphatidylcholine specific phospholipase (PC-PLC). According to the invention, the wide and deep research is carried out, the unexpected discovery is realized for the first time, the expression of metallothionein is up-regulated by the D609; the oxidative damage of RPE cellscan be effectively inhibited; therefore, the compound can be used for preventing or treating retinal injury diseases caused by oxidative stress injury of retinal pigment epithelial cells, especially,the compound can be extremely effectively used for preventing or treating macular degeneration diseases of retina, has no obvious drug toxicity, can effectively control the occurrence and developmentof injury diseases of retina, and provides a new theoretical support for developing unknown biological activity of D609 and future clinical treatment effects.

The invention relates to a method for inducing neural stem cells to be differentiated into neurons and astrocytes by umbilical cord mesenchymal stem cells. The method comprises the following steps: (1) culturing the third generation of human umbilical cord mesenchymal stem cells; (2) co-culturing double antibodies by using DF12 and 2% serum for 24 hours, and then carrying out flow cytometry; (3) co-culturing and inducing into neural stem cells by using 2% of serum, 2% of B27, DF12, 20 ng/mL of EGF, 20 ng/mL of BFGF, 10 [mu] M of Forskolin, 1 mM of IBMX and 35 ng/mL of dbcAMP, and then adding differentiation factors; (4) detecting expressions of markers of four neural stem cells, namely Netin, PAX6, SOX1 and SOX2, by using immunofluorescence and fluorescent quantitative PCR; and (5) detecting the expression of the glial cell marker GFAP and the neuron marker MAP-2 by using an immunofluorescence technology and a fluorescent quantitative PCR technology. According to the invention, multiple factors are used in a combined manner, the addition amount is optimized, neurons and astrokeratinocytes can be differentiated at the same time, the marker is highly expressed, and the induction rate of umbilical cord mesenchymal stem cells to induce neural stem cells is improved, so that the neural stem cells can be obtained to be used for treating neuronal injury diseases.

The invention provides a method for preparing neuron-like cells sourced from humanized adipose-derived stem cells. The method includes following steps: pre-incubating the humanized adipose-derived stem cells through a wnt pathway inhibitor, such as DKK1; inducing the pre-incubated humanized adipose-derived stem cells to differentiate into the neuron-like cells; and promoting the obtained neuron-like cells to mature by means of neurotrophic factors, such as BDNF, NGF and NT3. The neuron-like cells sourced from humanized adipose-derived stem cells are highly matured, can express mature nerve cell markers and ion channels and can enable a complex synapse structure to be observed so that the neuron-like cells can be used for treating neurodegenerative diseases and nervous-injury diseases and preparing corresponding medicines.

The invention discloses an application of chrysin in preparing an anti-hypoxic drug. The anti-hypoxic drug is a drug for preventing and treating hypoxic injury diseases which are high-altitude low-pressure oxygen deficit-caused acute high altitude diseases, cerebral ischemia hypoxic diseases or myocardial ischemia hypoxic diseases. The application has beneficial effects as follows: experiments prove that the chrysin has a remarkable anti-hypoxic effect, and effect tending to be better than that of acetazolamide; the anti-hypoxic drug prepared by applying the chrysin as an active ingredient can be used for preventing and treating hypoxic injuries or treating various hypoxic pathological states caused by oxygen content drop in external environment, also can be used for preventing or treating hypoxic pathological states of heart, brain, respiratory system, and the like as external normal oxygen cannot sufficiently get to a body due to diseases, and the like, and further can be used for preventing or treating the pathological state that relative oxygen supply is insufficient as oxygen consumption needed for activities of the body exceeds physiological mobilization ability.

The invention relates to the field of medicinal chemistry, in particular to dendrobium alkaloid derivatives (I); pharmacodynamic experiments prove that the compounds provided by the invention has protection activity for neuron injury caused by N-methyl-D-aspartate receptor (NMDA), thus being used for preventing and treating neuron injury diseases. (The structural formula of the dendrobium alkaloidderivatives (I) is described in the description.).

The invention relates to novel application of heat shock protein 20(HSP20), in particular to application of the HSP20 in preparing a drug for preventing and treating oxidative stress injury diseases.The invention further provides a building method of a mouse with high HSP20 expression in an AEC. The HSP20 has the advantages that it is found for the first time that HSP20 can be expressed when theAEC is subjected to oxidative stress and has an oxidation resistance effect, the expression of the HSP20 in the AEC is improved, the oxidation resistance of the AEC itself is improved, then the occurrence of the oxidative stress injury is prevented, and the HSP20 can be used for resisting ill effects of oxidative stress relevant to chronic air flue diseases, and has a very good clinical application prospect. By means of the novel application of the heat shock protein 20(HSP20), it is found for the first time that the HSP20 can be subjected to oxidative stress inducible expression, and has an oxidation resistance protection effect. It is found for the first time that the mechanism of the oxidation resistance protection effect of the HSP20 is relevant to regulation of an Nrf2-NQO-1 signal channel by the HSP20.

The Claimed Invention is the topical-to-skin use of generic estradiol, estriol, conjugated estrogens, or any other synthetic estrogen within a non-absorbable generic vehicle of cream, lotion, ointment, shampoo, hair tonic, and wound-healing powder, having no absorbents or deconstructors in their formulas. This invention causes skin basal cells to produce increased quantities of collagen and to retain skin-water resulting in increased skin-thickness. This increased thickness results in improved resilience, resistance to injury, trauma and infection. The target of this invention is the skin and skin only. Specifically, there is no intended absorption of hormone into the circulation to result in side effects or risk. Any possible unintended and minimal quantity of hormone absorbed would be metabolized normally by the liver and excreted in the urine without risk or awareness to the user. Improving skin health and healing existing injuries/disease can save individuals from mid 30's and older, and society in general millions of dollars annually in skin-related health care costs.

The invention relates to a method for detecting cortical neuron axonal growth guidance. The method comprises the following steps: preparing a stamp with a microscopy channel on a mold through polydimentylsiloxane, buckling the stamp on a glass slide for coating poly-L-lysine, adding a solution containing guidance factors and fluorescent molecules from one side of the channel so as to form parallel stripes with equal intervals after entering ducts; and performing neuron cultivation on the glass slide coated with the fluorescent stripe, observing whether newborn axon enters the stripe containing the guidance factors, and computing proportion of the newborn axon and the stripe, statistically analyzing. The method disclosed by the invention is not only in favor of understanding the forming mechanism of the neural circuit in a brain, but also has potential treatment value to the axonal degeneration and axonal injury diseases. On the basis of the method for detecting the cortical neuron axonal growth guidance, a disease model is established, the specificity expression of the secretion factor in the brain in the time and the space is simulated through exogenously giving cell secretion factor, the functional reconstruction of the neutron is induced, and the experimental basis is established for clinical translational medicine for treating above diseases.

The invention relates to a method for culturing a mesenchymal stem cell from an umbilical cord and an application thereof. Particularly the mesenchymal stem cell is obtained by performing isolated culture on an umbilical cord tissue discarded by a full-term caesarean puerpera. A simple method for culturing plenty of seed cells is provided for treating a tissue injury disease and researching a regenerative medicine through the mesenchymal stem cell. The method is strong in practicability without animal content and is safe to use.

The invention provides application of crocin in preparation of a medicine for repairing blood-brain barrier injury. By means of a recognized model that the specific blood-brain barrier of a nucleus accumbens septi brain region is damaged due to social contusion stress, it is found that crocin can obviously repair the blood-brain barrier and improve the three core indexes of blood-brain barrier damage, specifically, expression of Cldn5 of the nucleus accumbens septi brain region is increased, leakage of exogenous IL-6 to brain parenchyma of the nucleus accumbens septi brain region is reduced, and the continuity of vascular basement membranes is improved. In addition, by means of crocin administration, the pleasant sensation deficiency-like depression behavior of mice can be improved, and the learning and memory ability of the mice can be improved. The invention discloses oral crocin capable of repairing the damaged blood brain barrier, and provides a candidate medicine with a brand new mechanism for clinically repairing the blood brain barrier injury and treating related central function injury diseases.

The invention discloses application of a purine 2Y12 receptor antagonist in preparing medicine for diabetic neuropathological damage diseases. Experiments verify that the purine 2Y12 receptor antagonist can lower expression of dorsal root ganglion satellite glial cell purine 2Y12 receptor and reduce inflammatory medium release, and prompts that the purine 2Y12 receptor antagonist can inhibit transmission of nociceptive information mediated by the dorsal root ganglion purine 2Y12 receptor and relieve diabetic rat nerve injury and related diseases (including diseases like neuropathic pain), andthe purein 2Y12 receptor antagonist can be applied in preparing drug for treating diabetic neuropathological injury related diseases and neuropathic pain.

The invention relates to an application of FTO (Fat mass and obesity associated) protein as a target in treatment of pressure-loaded myocardial injury. It is proved that after a heart is stimulated bypressure overload, FTO down-regulation is an important cause of myocardial damage; a mouse with overexpression FTO pressure-loaded myocardial injury is obviously increased in myocardial sugar uptakeand obviously improved in cardiac function compared with those of a mouse in a model group, so that the overexpression FTO can treatment myocardial injury after pressure overload, and FTO is a drug target for treatment of pressure-loaded myocardial injury. The invention further provides an FTO overexpression vector with a remarkable curative effect. The application has the advantages that the application of the FTO as the treatment target for improving the pressure-loaded myocardial injury is developed, and a new drug research direction is provided for the pressure-loaded myocardial injury disease; and the invention provides a myocardial injury drug after pressure overload with FTO as the target, and the drug has a clinical application prospect.

Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.

The invention relates to the fields of biological medicine and chemistry, provides a butyl phthalide derivative and application thereof in preparation of a medicine for protecting nerve cells. More specifically, the invention provides application of the butyl phthalide derivative or a pharmaceutical composition composed of the butyl phthalide derivative to preparation of drugs for preventing and/or treating cell injury related diseases and neurodegenerative diseases. The nerve cell injury diseases include but are not limited to stroke, spinal injury and nervous system diseases accompanied with blood-brain barrier injury; and the neurodegenerative disease includes, but is not limited to, Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, primary lateral sclerosis, or spinal cerebellar ataxia.